19,557 Shares in Icon Plc $ICLR Acquired by D.A. Davidson & CO.

D.A. Davidson & CO. bought a new stake in shares of Icon Plc (NASDAQ:ICLR) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 19,557 shares of the medical research company’s stock, valued at approximately $3,422,000.

Several other hedge funds and other institutional investors have also modified their holdings of ICLR. Private Trust Co. NA raised its position in Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after buying an additional 94 shares during the period. Ameritas Advisory Services LLC purchased a new position in Icon during the 2nd quarter valued at about $48,000. LRI Investments LLC acquired a new position in shares of Icon in the 2nd quarter valued at about $49,000. Blue Trust Inc. lifted its position in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after purchasing an additional 120 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Icon by 40,800.0% in the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after purchasing an additional 408 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ICLR shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th. Cowen reissued a “hold” rating on shares of Icon in a research report on Friday, October 24th. TD Cowen dropped their target price on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research report on Friday, October 24th. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Finally, Bank of America downgraded Icon from a “buy” rating to a “neutral” rating and set a $195.00 price target for the company. in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $204.56.

Icon Stock Down 7.2%

ICLR stock opened at $188.22 on Friday. The stock has a market capitalization of $15.20 billion, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 4.24 and a beta of 1.26. The company has a 50-day moving average of $177.07 and a two-hundred day moving average of $172.51. Icon Plc has a 52-week low of $125.10 and a 52-week high of $220.93. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.